Characterization and functional analysis of *Toxoplasma* Golgi-associated proteins

identified by proximity labelling

Authors:

Rebecca R. Pasquarelli[1], Justin J. Quan[2], Emily S. Cheng[2], Vivian Yang[1], Timmie A.

Britton[1], Jihui Sha[3], James A. Wohlschlegel[3], and Peter J. Bradley[1,3*]

[1]Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA

[2]Department of Microbiology, Immunology, and Molecular Genetics, University of

California, Los Angeles, CA 90095, USA

[3]Department of Biological Chemistry and Institute of Genomics and Proteomics,

University of California, Los Angeles, California, USA

Running head: Characterization of *Toxoplasma* Golgi proteins

* Corresponding author: pbradley@ucla.edu, tel. 310-825-8386, fax 310-825-5231

Abstract

Toxoplasma gondii possesses a highly polarized secretory pathway that contains

both broadly conserved eukaryotic organelles and unique apicomplexan organelles which

play essential roles in the parasite's lytic cycle. As in other eukaryotes, the *T. gondii* Golgi

apparatus sorts and modifies proteins prior to their distribution to downstream organelles.

Many of the typical trafficking factors found involved in these processes are missing from

apicomplexan genomes, suggesting that these parasites have evolved unique proteins to

fill these roles. Here we identify a novel Golgi-localizing protein (ULP1) which contains

structural homology to the eukaryotic trafficking factor p115/Uso1. We demonstrate that

depletion of ULP1 leads to a dramatic reduction in parasite fitness and replicative ability.

Using ULP1 as bait for TurboID proximity labelling and immunoprecipitation, we identify

eleven more novel Golgi-associated proteins and demonstrate that ULP1 interacts with

the *T. gondii* COG complex. These proteins include both conserved trafficking factors and

parasite-specific proteins. Using a conditional knockdown approach, we assess the effect

of each of these eleven proteins on parasite fitness. Together, this work reveals a diverse

set of novel *T. gondii* Golgi-associated proteins that play distinct roles in the secretory

pathway. As several of these proteins are absent outside of the Apicomplexa, they

represent potential targets for the development of novel therapeutics against these

parasites.

Importance

Apicomplexan parasites such as *Toxoplasma gondii* infect a large percentage of

the world's population and cause substantial human disease. These widespread

pathogens use specialized secretory organelles to infect their host cells, modulate host

cell functions, and cause disease. While the functions of the secretory organelles are now

better understood, the Golgi apparatus of the parasite remains largely unexplored,

particularly regarding parasite-specific innovations that may help direct traffic

intracellularly. In this work, we characterize ULP1, a protein that is unique to parasites but

shares structural similarity to the eukaryotic trafficking factor p115/Uso1. We show that

ULP1 plays an important role in parasite replication and demonstrate that it interacts with

the conserved oligomeric Golgi (COG) complex. We then use ULP1 proximity labelling to

identify eleven additional Golgi-associated proteins which we functionally analyze via

conditional knockdown. This work expands our knowledge of the *Toxoplasma* Golgi

apparatus and identifies potential targets for therapeutic intervention.

Introduction

Toxoplasma gondii is an obligate intracellular parasite in the phylum Apicomplexa. This phylum includes parasites of both human and veterinary medical importance including Plasmodium spp. (malaria), Cryptosporidium spp. (diarrheal disease), Eimeria spp. (chicken coccidiosis), and Neospora caninum (neosporosis) (1–5). Approximately one-third of the global human population is chronically infected with T. gondii (6). While infection is usually asymptomatic in healthy individuals, the parasite can cause severe or fatal disease in immunocompromised people and congenitally infected neonates (7–9). While treatments exist that can suppress the acute infection, they are unable to clear the parasite completely resulting in lifelong chronic infection (8). A deeper understanding of apicomplexan biology is needed to inform the discovery of novel parasite-specific therapeutics.

Apicomplexan parasites possess a unique and highly polarized secretory pathway which plays an essential role in their life cycles (10,11). The endomembrane system of these parasites includes the endoplasmic reticulum and a Golgi apparatus, which is composed of a single stack of three to five cisternae, as well as several apicomplexan-specific organelles including the rhoptries, micronemes, dense granules, and inner membrane complex (IMC) (12,13). During parasite replication, these organelles are formed de novo from vesicles which bud from the Golgi and are trafficked through the secretory pathway to their destinations (14). The secretory pathway also delivers cargo to the plant-like vacuole (PLVAC), endosome like compartment (ELC), and a non-photosynthetic plastid called the apicoplast (15–18). As each of these organelles are essential, correct protein sorting is important for the survival of the parasite.

Recent studies have revealed a surprising intersection between T. gondii's endocytic and exocytic pathways. Several Rabs which are components of the endosomal system in most eukaryotes, such as Rab5a and Rab7, have instead been repurposed as

secretory trafficking proteins that reside in the ELC. The PLVAC, a hydrolytic compartment

analogous to the lysosome, has been implicated in multiple roles such as autophagy,

degradation of host-derived proteins, and proteolytic processing of proteins that are

trafficked to the micronemes and rhoptries (16,19,20). Disruption of proteins that localize

to the PLVAC and ELC or proteins that are typically involved in endosomal trafficking has

been shown to cause defects in the biogenesis of rhoptries and micronemes (11,16,21–

23). Furthermore, endolysosomal proteases have been shown to proteolytically process

immature ROP and MIC proteins (16,19,20). Together, this evidence supports the

convergence of endocytic and exocytic pathways in *T. gondii*.

Several key trafficking factors that play critical roles in protein trafficking in most

eukaryotes are missing in apicomplexan genomes. Specifically, *T. gondii* and other

apicomplexans lack most components of the Endosomal Sorting Complexes Required for

Transport (ESCRT) and the Golgi-localized Gamma adaptin ear-containing ARF-binding

(GGA) proteins (11,24,25). This limited repertoire of classical protein trafficking machinery

suggests that apicomplexans may have evolved their own specialized proteins and

pathways to facilitate these functions. Here we report the identification of a novel parasite-

specific Golgi protein, ULP1, which is structurally homologous to the eukaryotic tethering

factor p115/Uso1. We show that ULP1 plays a critical role in parasite fitness and its

depletion results in defective parasite replication. We then use TurboID proximity labelling

and immunoprecipitation to show that ULP1 interacts with the *T. gondii* conserved

oligomeric Golgi (COG) complex and identify eleven previously uncharacterized Golgi-

associated proteins. Finally, we analyze the orthology of each novel protein and use a

conditional knockdown approach to assess their impact on parasite fitness, revealing

several essential proteins and several more parasite-specific proteins.

Results

TGGT1_289120 is a parasite-specific Golgi protein that is important for parasite fitness

We identified a 290 kDa hypothetical protein with the gene ID TGGT1_289120 during our previous proximity labelling experiments using IMC proteins as bait (26). BLASTp analysis revealed that TGGT1_289120 has orthologs in *Hammondia*, *Neospora*, *Besnoitia, Cystoisospora*, and *Sarcocystis* but appears to be absent from other apicomplexan parasites and higher eukaryotes (27). Secondary structure analysis using Phyre2 revealed that residues 495-647 of TGGT1_289120 contain structural homology to the globular head domain of p115/Uso1, a membrane tethering protein conserved in eukaryotes (28,29). InterPro also identified an armadillo (ARM)-like domain within this region, and DeepCoil2 predicted a coiled-coil (CC) domain within residues 1736-1812 (Fig 1A) (30,31). p115/Uso1 also contains ARM repeats within its globular head domain and a single CC domain near the C-terminus, further supporting their structural similarity (29). While this study was being prepared for publication, a study of the *T. gondii* COG complex by Marsilia et al. independently identified TGGT1_289120 and named it Uso1-like protein 1 (TgULP1) based on its structural similarity to the p115/Uso1 protein (32). To maintain consistency, we adopted the same nomenclature and also named the protein ULP1.

The similarity to the essential vesicular trafficking factor p115/Uso1 and its low phenotype score of -3.8 in a genome wide CRISPR/Cas9 screen (GWCS) led us to hypothesize that this protein may play a key role in secretory trafficking in *T. gondii* (33). To determine the localization of ULP1, we used CRISPR/Cas9 to fuse sequences encoding a C-terminal 3xHA epitope tag at its endogenous locus (34,35). Immunofluorescence assay (IFA) revealed that ULP1 localized to a distinct bar-shaped region anterior to the nucleus, suggesting localization to the Golgi apparatus. To confirm

this, we co-stained for GRASP55-YFP, a marker of the cis-medial Golgi apparatus in *T.*

gondii and found that the two proteins colocalized (Fig 1B) (36).

To study the function of ULP1, we used the auxin-inducible degron (AID) system

which allows rapid proteasomal degradation of a target protein upon treatment with

indoleacetic acid (IAA) (37,38). To create an ULP1[AID] parasite strain, we fused sequences

encoding an mAID-3xHA tag to the 3' end of the gene in a strain that carries the TIR1

auxin-receptor FBOX protein. IFA showed that the degron-tagged protein localizes

appropriately and is completely depleted after 24 hours of IAA treatment (Fig 1C). The

ULP1-depleted parasites did not appear to exhibit defects in overall morphology. To

assess how loss of ULP1 would affect the parasite's overall lytic ability, we performed

plaque assays, which showed a dramatic 88.7% decrease in plaque size when ULP1 was

depleted (Fig 1D, E). To determine whether this defect in lytic ability was due to defects in

replication, we quantified the number of parasites per vacuole after 30 hours of growth for

parasites treated with IAA or a vehicle control. At 30 hours post-infection, ULP1-depleted

parasites were found primarily in 8-parasite vacuoles, whereas untreated parasites were

primarily found in 16-parasite vacuoles (Fig 2F). This indicates that the defect in overall

lytic ability is due to a defect in replication. Given the low phenotype score (-3.8), we

wondered whether the slow growth and ability to form small plaques may be due to some

residual ULP1 which escaped degradation. To determine if this was the case, we used

CRISPR/Cas9 to disrupt the endogenous locus for ULP1 and verified loss of the protein

by both IFA and PCR (Fig 1G-H). Using this method, we successfully generated a Δ*ulp1*

strain which phenocopied the plaque defect exhibited by IAA-treated ULP1[AID] parasites

(Fig 1I-J). To avoid potential issues with functional compensation, which has been

previously documented for knockout strains in *T. gondii*, we decided to proceed with the

ULP1[AID] strain for further phenotypic analysis (39–41).

Next, we used IFA to assess whether depletion of ULP1 resulted in aberrant

organellar morphology. We began by endogenously tagging the known Golgi protein

TgTrs85 to determine whether loss of ULP1 would affect the Golgi apparatus (18). When

we depleted ULP1, we found that TgTrs85 was unaffected (Fig 2A). We next stained for

DrpB, a dynamin-related protein that localizes to post-Golgi vesicles, which also appeared

to be unaffected (Fig 2B) (23). Other components of the secretory pathway such as the

PLVAC (marked by NHE3), endoplasmic reticulum (SERCA), and ELC (Vps9) were

similarly unaffected (Fig 2C-E). Next, we wanted to determine whether the morphology of

downstream secretory organelles was altered, so we stained for the rhoptries (ROP7),

micronemes (MIC2), and dense granules (GRA14). We additionally stained for the

apicoplast (Atrx1) and mitochondrion (F1β ATPase). Surprisingly, we did not observe

mislocalization of any of these markers, indicating these organelles are not grossly

affected upon ULP1 knockdown (Fig 2F-J).

ULP1 proximity labelling and immunoprecipitation yields candidate Golgi proteins

To identify additional novel Golgi proteins, we decided to use ULP1 as bait for both

proximity labeling and immunoprecipitation (IP) experiments. For proximity labelling, the

biotin ligase TurboID-3xHA was fused to the C-terminus of ULP1 (Fig 3A) (42). The

ULP1^{TurboID} fusion protein was detectable by IFA and trafficked appropriately to the Golgi

apparatus. In the absence of biotin, only the endogenously biotinylated apicoplast stained

with streptavidin. Upon addition of biotin, the Golgi apparatus also stained with

streptavidin, confirming that the ULP1^{TurboID} fusion protein was enzymatically active and

biotinylated proximal Golgi proteins (Fig 3B). Western blot analysis confirmed that the

addition of biotin resulted in dramatically increased amounts of biotinylated proteins in

ULP1^{TurboID} lysates (Fig 3C). The IP analysis was performed on the ULP1^{3xHA} strain.

Western blot showed that the 3xHA-tagged protein migrated at a smaller size than

expected based on its molecular weight of 290 kDa and exhibited significant protein

breakdown. During the process of affinity chromatography for the IP experiment, the

protein experienced even more severe breakdown. Despite this, the elution fraction was

still highly enriched for the HA-tagged protein (Fig 3D). Thus, we continued with the

experiment.

As expected, the bait protein ULP1 was the top hit identified by mass spectrometry

in the IP experiments and was among the top 5 hits in the TurboID experiment (Table S1

and Table S2). DrpB, TgTrs85, TgEpsL, and Vps9, which have all been previously shown

to localize to the *Toxoplasma* Golgi apparatus or nearby compartments of the secretory

pathway, were highly enriched in our TurboID experiment (Table S1) (18,23,43,44). In

addition, many of the top hits are predicted to be involved in processes such as ER-to-

Golgi retrograde transport, Golgi organization, and intracellular protein transport. Many of

the most enriched proteins were hypothetical proteins that have not previously been

studied. Domain analysis allowed us to identify two of these hypothetical proteins,

TGGT1_278890 and TGGT1_262450, as homologs of the known Golgi proteins CDP/cut

alternatively spliced product (CASP) and dymeclin (DYM), respectively.

Our IP experiment identified several interesting candidate interactors, including the

hypothetical protein TGGT1_216370, which was also among the top hits in the TurboID

experiment (Table S2). In addition, homologs of all eight subunits of the COG complex

immunoprecipitated with ULP1 and were highly enriched in our TurboID experiment. All

eight are currently annotated as hypothetical proteins, but BLASTp and functional domain

analysis supports their designation as COG complex subunits, although the BLASTp e-

value for COG1 is weak (e^{-6}) (24). As p115/Uso1 is a known interactor of the COG complex

via direct binding to COG2, this result further supports the designation of ULP1 as a

p115/Uso1-like protein (45). Several additional proteins were found to immunoprecipitate

with ULP1, although fewer peptides were recovered for these proteins. Among these lower

abundance hits were a Sec23/Sec24 trunk domain-containing protein, TgEpsL, COP1

subunit ε, the cyclin-dependent kinase (CDK)-related kinase Crk2, Vps35, Rab7, AP1-γ,

and DrpB.

Verification of candidate Golgi proteins

To continue our study of the *Toxoplasma* Golgi apparatus, we selected eleven

uncharacterized proteins with GWCS phenotype scores of less than -2 from our TurboID

and IP hits (Table 1). Candidates were prioritized based on functional domain analysis

and orthology to known Golgi proteins. Five of the selected genes appeared to be direct

orthologs of known Golgi-associated proteins. TGGT1_290310 is the putative COG1

orthologue that we identified in our ULP1 IP. TGGT1_311400 is annotated as WD domain,

G-beta repeat-containing protein, but BLASTp analysis revealed its identity as Sec31.

TGGT1_232190 contains a Sec7 domain within a larger Golgi Brefeldin A resistance

guanine nucleotide exchange Factor 1 (GBF1) domain. TGGT1_264090 contains a

TRAPPC11 domain. TGGT1_301410 contains both an ENTH domain and a Tepsin

domain. Two proteins contain functional domains that suggested they may have functions

related to the secretory system, but do not appear to be direct orthologs of any known

Golgi proteins. TGGT1_294730 contains an ancestral coatomer element 1 (ACE1) domain

from Sec16/Sec31 yet lacked other key domains found in these proteins. TGGT1_230400

contains a WIP-related protein domain but appears to only have orthologs in other

coccidian parasites (46). The final four selected genes (TGGT1_216370, TGGT1_207370,

TGGT1_258080, and TGGT1_240220) are hypothetical proteins that contained no

identifiable functional domains aside from predicted CC domains and had orthologs only

in cyst-forming coccidia.

To verify these candidate Golgi proteins, we endogenously tagged each protein at

its C-terminus with an auxin-inducible degron coupled to a 3xHA epitope tag in a TIR1

strain (37). We then expressed the Golgi marker GRASP55-YFP in each line and used

IFA to assess the localization of each gene (36). All eleven genes either colocalized with

GRASP55 or were closely adjacent, confirming their association with the *Toxoplasma*

Golgi apparatus (Fig 4). Based on their localization and functional domains, we assigned

names to each of the eleven proteins.

TGGT1_311400 was designated Sec31, TGGT1_294730 as Sec16-like protein (Sec16-

L), TGGT1_264090 as TRAPPC11-like protein (TRAPPC11), TGGT1_290310 as COG1,

TGGT1_232190 as GBF1, and TGGT1_230400 as WIP-related Protein Domain-

containing Protein (WPDP). The hypothetical protein TGGT1_258080 was also recently

identified by Marsilia et al., so we adopted their nomenclature and named it Golgi

Localizing Protein 1 (GLP1). The hypothetical proteins TGGT1_216370, TGGT1_207370,

TGGT1_240220 were designated as Golgi Localizing Protein 2, 3, and 4, respectively

(GLP2-4). Upon further inspection, we noticed that the extent to which each protein

colocalized with GRASP55 varied. Sec31, Sec16-L, and GLP3 appeared to localize

upstream of GRASP55 in the secretory pathway (Fig 4A, B, and H). Sec31 and Sec16 are

both known to localize to ER exit sites where they play roles in anterograde transport (47).

While GLP3 does not contain any domains that hint at its function, its similar localization

to Sec31 and Sec16-L suggests it may also play a role in early anterograde transport.

TRAPPC11, COG1, GBF1, GLP2, and WPDP all appeared to mostly colocalize with

GRASP55, indicating a primary localization in the cis-medial Golgi (Fig 4C-G and I).

TRAPPC11 and WPDP displayed some additional signal downstream of GRASP55,

suggesting they may also localize to the trans Golgi network (Fig 4C and G). Finally,

Tepsin, GLP1, and GLP4 localized downstream of GRASP55, indicating that they likely

are restricted to the trans Golgi network (Fig 4J and K).

Functional analysis of novel proteins

263   We next used the AID system to assess how depletion of each novel Golgi protein

264 would affect parasite fitness. Five of the eleven strains (Sec31, GBF1, COG1, Tepsin,

265 and TRAPPC11) were found to be completely deficient in plaque formation, indicating that

266 these proteins are essential for parasite survival (Fig 5A). Sec31 exhibited a severe growth

267 arrest, with nearly all vacuoles containing only a single parasite after 24 hours of growth

268 in the presence of IAA (Fig 5B). Despite the severe growth defect, Sec31-depleted

269 parasites appeared to have normal overall morphology as assessed by IMC6 staining.

270 GBF1 also exhibited a severe growth arrest (Fig 5C). However, in contrast to Sec31, many

271 GBF1-depleted parasites also exhibited defective IMC morphology. Both COG1 and

272 Tepsin-depleted parasites did not exhibit growth arrest at 24 hours but had severe defects

273 in morphology, such as large gashes in the cytoskeleton marked by IMC6 (Fig 5D, E). The

274 last essential protein, TRAPPC11, did not exhibit growth arrest or any apparent defects in

275 overall morphology as assessed by IMC6 staining after 24 hours of IAA treatment (Fig

276 5F).

277   The remaining six proteins were found by plaque assay to be non-essential, but

278 their depletion resulted in a statistically significant reduction in lytic ability (Fig 6A). The

279 severity of the defect varied widely among the six proteins. The most severe growth defect

280 (91.8%) was observed for GLP2. The remaining five proteins exhibited more modest

281 reductions – 25.7% for Sec16-L, 21.0% for WPDP, 14.2% for GLP1, 40.5% for GLP3,

282 37.9% for GLP4. Despite the reduction in fitness, all six of these proteins exhibited no

283 obvious defects in morphology by IFA (Fig 6B-G).

285 **Discussion**

286   In this study, we identified and characterized the novel Golgi protein ULP1 as a

287 critical regulator of parasite growth and used it as a probe to identify and characterize

288 additional novel Golgi proteins. Our analysis of ULP1 demonstrated that the protein

localizes to the cis-medial Golgi and plays an important role in parasite replication. Loss

of the protein by either AID-mediated knockdown or gene knockout resulted in a severe

defect in plaque size. Our findings contrast with that of Marsilia et al. who showed a

complete loss of lytic ability upon ULP1 knockdown and place its primary localization in

the trans-Golgi network (32). While the conditional knockdown strains may vary in the

phenotypes observed, the ULP1 knockout indicates that the protein is not strictly required

for parasite survival. ULP1 is an interesting protein because it is unique to cyst-forming

coccidia yet is structurally homologous to the conserved eukaryotic trafficking factor

p115/Uso1. Studies in mammalian cells, *Drosophila*, and yeast have demonstrated that

p115/Uso1 has a wide range of essential functions including tethering COPI vesicles to

the Golgi, transporting vesicles from the ER to the Golgi, and facilitating SNARE complex

assembly (48–53). Loss of p115/Uso1 has been shown to result in fragmentation of the

Golgi and accumulation of Golgi-derived vesicles (54). In addition to its localization to the

Golgi apparatus, the protein has been observed associating with the spindle poles, and

loss of the protein has been shown to impair mitosis (55,56). While we did not identify any

apparent defects in trafficking of markers to key secretory organelles or loss of Golgi

integrity upon ULP1 knockdown, we did observe a significant reduction in replicative ability

which could suggest that ULP1 plays a role in cell cycle regulation, similar to p115/Uso1.

P115/Uso1 is known to interact with several trafficking proteins including Rab1,

GBF1, COG2, GM130, and SNARE complex components Syntaxin 5, Bet1 and Bos1

(45,51,57–59). Our IP analysis was highly enriched for all eight COG complex subunits,

with COG2 being the second most enriched. Marsilia et. al also identified all eight

components of the COG complex in their ULP1 IP, further supporting the legitimacy of

these interactions (32). Interestingly, we did not identify any of the other known p115/Uso1

interacting proteins. While these other proteins may have been lost during processing, it

is also possible that ULP1 function has diverged enough from p115/Uso1 such that it does

not bind to these proteins and instead uses other parasite-specific proteins to fulfill these

roles. Supporting this, the novel Golgi protein GLP2 was found to IP with ULP1 in both

Marsilia et. al and our study. p115/Uso1 has been shown to bind to Cdk1 and loss of p115

was demonstrated to reduce Cdk1 activation (56). Interestingly, we identified a CDK-

related kinase, Crk2, in our IP analysis. Given that ULP1 depletion leads to a decrease in

replication rate, it is possible that interaction with Crk2 plays a role in *T. gondii* mitosis.

Alternatively, the replication defect could be due to general ER stress caused by alteration

of the secretory pathway (60). When comparing the remaining results of our IP with

Marsilia et. al, several differences are observed. They identified a wide variety of other

proteins including eight SNARE proteins, four AP-5 complex proteins, and five COPI

complex subunits that were either absent from our analysis or did not reach the two-fold

enrichment cut-off. Additionally, the authors noted that over 20 IMC proteins and Rab11b,

which is critical for IMC biogenesis, were enriched in their ULP1 IP. However, we did not

observe enrichment for any of these proteins. Similarly, our IP identified Crk2, Rab7,

Vps35, TgEpsL, AP1-γ, and a Sec23/Sec24 trunk domain-containing protein while the

other study did not. These disparities likely arise from differences in sample processing,

and further analysis of ULP1 binding partners will be needed to create a more definitive

picture of the ULP1 interactome.

Using ULP1 as bait in both TurboID and IP experiments, we were able to identify

11 previously uncharacterized Golgi-associated proteins. Sec31, COG1, GBF1, Tepsin,

and TRAPPC11 were found to be essential, which is unsurprising due to their critical

conserved functions in other eukaryotes. Two of these proteins, Sec31 and GBF1, caused

an immediate growth arrest upon depletion, likely due to a block in the secretory pathway

that prevents the continuation of the cell cycle. Sec31 acts as a component of the COPII

complex, which facilitates anterograde transport from the ER to the Golgi and causes

growth arrest when depleted in *Trypanosomes* (47,61,62). We observed the *T. gondii*

Sec31 localizing upstream of GRASP55 in the secretory pathway, indicating that it likely

localizes to ER exit sites as in other eukaryotes. The localization of this protein to this

subcompartment of the Golgi represents a valuable new marker for this region of the

secretory pathway in *T. gondii*. GBF1 is a Golgi-resident guanine nucleotide exchange

factor that regulates COPI vesicle-mediated transport by activating ADP-ribosylation

factor (Arf) proteins (63,64). We observed *Toxoplasma* GBF1 localizing to the cis-medial

Golgi, which agrees with its function in other systems.

Unlike Sec31 and GBF1, the remaining three essential proteins, COG1, Tepsin,

and TRAPPC11, did not exhibit an immediate growth arrest upon depletion. COG1 is a

component of the COG complex, which acts in the retrograde transport pathway by

tethering COPI-coated vesicles that are used for recycling Golgi-resident enzymes such

as glycosyltransferases back to the Golgi (65,66). Several *T. gondii* proteins such as

GAP50 and CST1 have been shown to be glycosylated, and this modification is required

for their proper targeting and function (67,68). In agreement with this, Marsilia et. al

demonstrated that O-glycosylation is disrupted upon COG3 or COG7 depletion (32). This

function is primarily carried out in the cis/medial Golgi, which matches our observed

colocalization of COG1 with GRASP55. Tepsin is an accessory protein that associates

with the AP-4 complex, which plays a role in vesicular trafficking of proteins at the trans-

Golgi network (69,70). Knockdown of either COG1 or Tepsin resulted in severe defects in

IMC morphology, suggesting that loss of either protein causes issues with the secretory

pathway ultimately leading to defects in IMC biogenesis. TRAPPC11, on the other hand,

did not exhibit any obvious morphological defects. TRAPPC11 was observed colocalizing

with GRASP55 in the cis-medial Golgi. Since TRAPPC11 functions in anterograde vesicle

transport as a member of the TRAPPIII tethering complex, it is possible that *Toxoplasma*

TRAPPC11 could play a key role in trafficking of effector proteins like ROPs and MICs,

leading to a defect in invasion and/or egress (71). Further studies will be needed to assess

precisely how each of these essential proteins affects parasite fitness.

Two of the identified proteins, Sec16-L and WPDP, do not appear to be direct

orthologs of known Golgi proteins but contain domains that suggested conserved

functions. Sec16-L contains the ACE1 domain from Sec16, an essential COPII vesicle

coat protein required for ER transport vesicle budding and formation of ER exit sites (72).

However, it is missing the Sec16 conserved C-terminal domain which facilitates binding

to Sec23 and is essential for function (73). Sec16-L's localization upstream of GRASP55

further supports its functional similarity to Sec16 and provides another marker of this early

subcompartment of the secretory pathway in addition to Sec31. While Sec16 is essential

in other systems, Sec16-L had a relatively modest fitness defect upon conditional

knockdown and its ortholog in *P. falciparum* (PF3D7_1119900) is also predicted to be

dispensable (74). It is possible that another protein has adopted this function in *T. gondii*

and other apicomplexans, rendering this protein redundant. WPDP contains a WIP-related

protein domain which is known to facilitate actin binding. Numerous Golgi-resident actin-

binding proteins have previously been identified in mammalian cells and the actin

cytoskeleton has been shown to be critical for maintaining Golgi structure and facilitating

vesicular trafficking (75). Similar to Sec16-L, WPDP had a modest phenotype upon

conditional knockdown. It is possible that WPDP may be one of several actin-binding

proteins that help maintain Golgi structure in *T. gondii* and related apicomplexans.

We additionally identified four novel parasite-specific Golgi proteins, GLP1-4,

which were all found to be non-essential. GLP3, which we identified as an interactor of

ULP1 by IP, was found to localize upstream of GRASP55 like Sec16-L and Sec31, and

therefore could play a role in ER to Golgi vesicle transport. GLP1 and GLP4 both localize

downstream of GRASP55, suggesting they function in the trans-Golgi network. Both

proteins exhibit only a relatively small reduction in plaque size upon their depletion.

Interestingly, the two proteins are similar in size and both contain a region with one larger

coiled-coil domain closely followed by two shorter coiled-coil domains. While their

sequence similarity does not suggest they are paralogs, their similar localizations,

phenotypes, and structural compositions could indicate possible functional redundancy.

Finally, GLP2 was found to localize to the cis-medial Golgi and caused a dramatic 91.8%

reduction in plaque size when depleted. Despite this, we did not observe any obvious

growth defects or morphological changes by IFA, suggesting that loss of GLP2 may affect

either invasion or egress rather than replication. Interestingly, all of the GLPs contain

several predicted coiled-coil domains and are only found in the cyst-forming coccidia.

Coiled-coil domain-containing proteins such as the golgin proteins GM130, giantin, and

CASP are known to act as tethering factors in other eukaryotes (76). As the GLPs are

unique to the cyst-forming coccidia, it is possible they could use their CC domains to act

as Golgi tethering factors that carry out unique functions in this subset of apicomplexan

parasites.

Together, this study reveals a total of 12 novel Golgi-associated proteins including

several that are essential and others that are parasite-specific. Their identification provides

valuable new markers for the secretory pathway and provides exciting candidates for

further functional analysis. Due to the apicomplexan-specific nature of several of these

proteins, they represent both novel cell biology and potential targets for therapeutic

intervention.

Materials and Methods

T. gondii and host cell culture

Parental *T. gondii* RHΔ*hxgprt*Δ*ku80* (wild-type) and subsequent strains were grown on confluent monolayers of human foreskin fibroblasts (BJ, ATCC, Manassas, VA) at 37°C and 5% CO_2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% fetal bovine serum (Gibco), 5% Cosmic calf serum (Hyclone), and 1x penicillin-streptomycin-L-glutamine (Gibco). Constructs containing selectable markers were selected using 1 µM pyrimethamine (dihydrofolate reductase-thymidylate synthase [DHFR-TS]), 50 µg/mL mycophenolic acid-xanthine (HXGPRT), or 40 µM chloramphenicol (CAT) (77–79). For AID conditional knockdown experiments, media was supplemented with 500 µM indoleacetic acid (Sigma-Aldrich; I2886) or vehicle control.

Antibodies

The HA epitope was detected with mouse monoclonal antibody (mAb) HA.11 (BioLegend; 901515). The V5 epitope was detected with mouse mAb anti-V5 (Invitrogen; R96025). *Toxoplasma*-specific antibodies include rabbit pAb anti-IMC6 (80), rat pAb anti-DrpB (23), guinea pig pAb anti-NHE3 (81), mouse pAb anti-SERCA (82), mouse mAb anti-ROP7 (1B10) (83), mouse mAb anti-MIC2 (6D10) (84), mouse pAb anti-GRA14 (83), mouse mAb anti-ATrx1 (11G8) (85), mouse mAb anti-F1β subunit (5F4) (86), and mouse pAb anti-ROP13 (87).

Endogenous epitope tagging and knockout

For C-terminal endogenous tagging, a pU6-Universal plasmid containing a protospacer against the 3′ untranslated region (UTR) of the target protein approximately 100 bp downstream of the stop codon was generated, as described previously (34). A

homology-directed repair (HDR) template was PCR amplified using the Δ*ku80*-dependent

LIC vector pmAID3xHA.LIC-HPT, pmIAA73xHA.LIC-HPT, p3xHA.LIC-DHFR, p3xV5.LIC-

DHFR, or pTurboID3xHA.LIC-DHFR, all of which include the epitope tag, 3′ UTR, and a

selection cassette (88). The 60-bp primers include 40 bp of homology immediately

upstream of the stop codon or 40 bp of homology within the 3′ UTR downstream of the

CRISPR/Cas9 cut site. For knockout of ULP1, the protospacer was designed to target the

coding region of ULP1, ligated into the pU6-Universal plasmid and prepared similarly to

the endogenous tagging constructs. The HDR template was PCR amplified from a pJET

vector containing the HXGPRT drug marker driven by the NcGRA7 promoter using

primers that included 40 bp of homology immediately upstream of the start codon or 40

bp of homology downstream of the region used for homologous recombination for

endogenous tagging. All primers that were used for pU6-Universal plasmids and HDR

templates are listed in Table S3.

For all tagging and knockout constructs, approximately 50 μg of the sequence-

verified pU6-Universal plasmid was precipitated in ethanol, and the PCR-amplified HDR

template was purified by phenol chloroform extraction and precipitated in ethanol. Both

constructs were electroporated into the appropriate parasite strain. Transfected cells were

allowed to invade a confluent monolayer of HFFs overnight, and appropriate selection was

subsequently applied. Successful tagging was confirmed by IFA, and clonal lines of

tagged parasites were obtained through limiting dilution.

Immunofluorescence assay

Confluent HFF cells were grown on glass coverslips and infected with *T. gondii*.

After 24 hours, the coverslips were fixed with 3.7% formaldehyde in PBS and processed

for immunofluorescence as described (87). Primary antibodies were detected by species-

specific secondary antibodies conjugated to Alexa Fluor 594/488 (ThermoFisher).

Coverslips were mounted in Vectashield (Vector Labs), viewed with an Axio Imager.Z1

fluorescent microscope and processed with ZEN 2.3 software (Zeiss).

Western blot

Parasites were lysed in 1x Laemmli sample buffer with 100 mM DTT and boiled at

100°C for 5 minutes. Lysates were resolved by SDS-PAGE and transferred to

nitrocellulose membranes, and proteins were detected with the appropriate primary

antibody and corresponding secondary antibody conjugated to horseradish peroxidase.

Chemiluminescence was induced using the SuperSignal West Pico substrate (Pierce) and

imaged on a ChemiDoc XRS+ (Bio-Rad).

Plaque assay

HFF monolayers were infected with 200 parasites per well of individual strains (-/+

IAA for AID strains) and allowed to form plaques for 7 days. Cells were then fixed with ice-

cold methanol and stained with crystal violet. To quantify plaque size, the areas of 50

plaques per condition were measured using ZEN software (Zeiss). To quantify plaque

number, the total number of plaques in each condition was counted manually. All plaque

assays were performed in triplicate. Graphical and statistical analyses were performed

using Prism GraphPad 8.0.

Quantification of parasites per vacuole

Parasites were pre-treated with IAA or vehicle control for 18 hours prior to infecting

coverslips. After coverslips were infected, parasites were allowed to grow -/+ IAA for 30

hours prior to fixation and staining with mouse anti-HA (detecting ULP1^{AID}) and rabbit anti-

IMC6. For each condition, the number of parasites per vacuole (1, 2, 4, 8, 16, or $\geq$32) was

counted for >100 vacuoles across 10 different fields. Experiments were performed in triplicate. Significance was determined using multiple two-tailed t tests.

Affinity capture of biotinylated proteins

For affinity capture of proteins from whole cell lysates, HFF monolayers infected with ULP1^{TurboID} or control parasites (RHΔ*hxgprt*Δ*ku80*, WT) were grown in medium containing 150 μM biotin for 30 hours. Intracellular parasites in large vacuoles were collected by manual scraping, washed in PBS, and lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) supplemented with Complete Protease Inhibitor Cocktail (Roche) for 30 min on ice. Lysates were centrifuged for 15 min at 14,000 x g to pellet insoluble material, and the supernatant was incubated with Streptavidin Plus UltraLink resin (Pierce) overnight at 4°C under gentle agitation. Beads were collected and washed five times in RIPA buffer, followed by three washes in 8 M urea buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl) (89). Samples were submitted for on-bead digests and subsequently analyzed by mass spectrometry. The experiment was performed in duplicate.

Immunoprecipitation assay

ULP1^{3XHA} was isolated from 5×10^9 *T. gondii* RH tachyzoites lysed in NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris [pH 8.0]) supplemented with complete protease inhibitor (Roche). The insoluble material was removed from the lysate by centrifugation at 10,000 x *g* for 20 minutes. The soluble lysate fraction was incubated with rat anti-HA affinity matrix (Roche) for 3 hours at room temperature with gentle agitation. After washing in NP-40 lysis buffer, the bound protein was eluted using high pH (100 mM triethylamine, pH 11.5), dried to a pellet, and submitted for mass spectrometry.

Mass spectrometry

Samples were resuspended in digestion buffer (8M Urea, 0.1M Tris-HCl [pH 8.5]) and then

were reduced, alkylated, and digested by sequential addition of Lys-C and trypsin

proteases. Samples were then desalted using C18 tips (Pierce) and fractionated online

using a 75-μm inner-diameter fritted fused silica capillary column with a 5-μm pulled

electrospray tip and packed in-house with 25 cm of C18 (Dr. Maisch GmbH) 1.9-μm

reversed-phase particles. The gradient was delivered by a 140-minute gradient of

increasing acetonitrile and eluted directly into a Thermo Orbitrap Fusion Lumos instrument

where MS/MS spectra were acquired by Data Dependent Acquisition (DDA). Data analysis

was performed using ProLuCID and DTASelect2 implemented in Integrated Proteomics

Pipeline IP2 (Integrated Proteomics Applications) (90–92). Database searching was

performed using a FASTA protein database containing *T*. *gondii* GT1-translated open

reading frames downloaded from ToxoDB. Protein and peptide identifications were filtered

using DTASelect and required a minimum of two unique peptides per protein and a

peptide-level false positive rate of less than 5% as estimated by a decoy database

strategy. Candidates were ranked by spectral count comparing experimental versus

control samples (93). TurboID results were filtered to include only proteins that were at

least two-fold enriched with a difference of >5 spectral counts when comparing ULP1[TurboID]

samples versus control samples. IP results were filtered to include only proteins that were

at least two-fold enriched when comparing ULP1[3xHA] IP samples versus control samples.

Bioinformatic analysis of novel proteins

Functional domains were identified using a combination of Phyre2, Interpro

Domains, PFAM, and Panther analysis (28,30,94,95). Coiled coil domains were predicted

using DeepCoil2 using a probability cut-off of 0.5 (31). Orthology was determined using

OrthoMCL and BLASTp search against the VEuPathDB database (46).

Acknowledgements

We thank Vern Carruthers for supplying the anti-MIC2 antibody, Gustavo Arrizabalaga for

supplying the anti-NHE3 antibody, and David Sibley for supplying the anti-SERCA

antibody. This work was supported by NIH grants AI123360 to P.J.B, and GM089778 to

J.A.W. R.R.P. and V.Y. were supported by the Ruth L. Kirschstein National Research

Service Award AI007323. R.R.P was additionally supported by the Ruth L. Kirschstein

National Research Service Award GM007185 and the UCLA Molecular Biology Institute

Whitcome Fellowship. J.J.Q was supported by a Milton Gottlieb endowment award and by

a Beckman Scholars Award through the Arnold and Mabel Beckman Foundation.

Competing Interests

The authors declare no competing interests.

Figure 1

A TGGT1_289120 (ULP1)
p115/Uso1-like domain | Coiled-Coil Domain

B Phase | ULP1^HA | GRASP55 | Merge

C -IAA: Phase | ULP1^AID | IMC6 | Merge
+IAA: Phase | ULP1^AID | IMC6 | Merge

D -IAA / +IAA

E Mean Plaque Area (mm²) | **** | -IAA +IAA

F Vacuoles (%) vs Parasites/Vacuole (1, 2, 4, 8, 16, ≥32) | – IAA / + IAA | *

G Phase | HA | IMC6 | Merge

H coding / ULP1 / HXGPRT — WT Δulp1 — coding, HXGPRT, 1 kb

I WT / Δulp1 — -IAA +IAA

J Mean Plaque Area (mm²) | **** | WT Δulp1

Fig 1. ULP1 is a novel Golgi-localizing protein that is important for parasite fitness.

A) Gene model of TGGT1_289120 (ULP1) showing its p115/Uso1-like domain and

predicted CC domain. B) IFA showing that ULP1 colocalizes with the Golgi apparatus

marker GRASP55-YFP. Magenta = anti-HA detecting ULP1[3xHA], Green = GRASP55-YFP.

C) IFA showing that ULP1[AID] localizes normally and is depleted after 24 hours of IAA

treatment. Magenta = anti-HA detecting ULP1[AID], Green = anti-IMC6. D) Plaque assay for

ULP1[AID] parasites -/+IAA shows that depletion of ULP1 results in a severe reduction in

overall lytic ability. E) Quantification of plaque size for plaque assays shown in panel D.

Significance was determined using two-tailed t test. **** = $P < 0.0001$. F) Quantification of

the number of parasites per vacuole for ULP1[AID] parasites treated with IAA or vehicle

control after 24 hours of growth. Significance was determined using multiple two-tailed t

tests. * = $P < 0.05$. G) IFA of Δ*ulp1* parasites confirms loss of ULP1[3xHA] signal. Magenta =

anti-HA, Green = anti-IMC6. H) PCR verification for genomic DNA of WT and Δ*ulp1*

parasites. Diagram indicates the binding location of primers used to amplify the ULP1

coding sequencing (blue arrows) and the site of recombination for the knockout (red

arrows). I) Plaque assays of WT and Δ*ulp1* parasites. J) Quantification of plaque size for

plaque assays shown in panel I. Statistical significance was determined using a two-tailed

t test. **** = $P < 0.0001$. Scale bars for plaque assays = 0.5 mm. Scale bars for IFAs = 2

μm.

Figure 2

Fig 2. Depletion of ULP1 does not affect overall organellar morphology. IFAs

comparing the overall morphology of various *T. gondii* organelles in control vs. ULP1-

depleted parasites. A) Golgi apparatus morphology is unaffected by depletion of ULP1.

Magenta = anti-V5 detecting TgTrs85^{3xV5}, Green = anti-IMC6. B) Post-Golgi vesicle

morphology is unaffected by depletion of ULP1. Magenta = anti-DrpB, Green = anti-IMC6.

C) PLVAC morphology is unaffected by depletion of ULP1. Magenta = anti-NHE3, Green

= anti-IMC6. D) ER morphology is unaffected by depletion of ULP1. Magenta = anti-

SERCA, Green = anti-IMC6. E) ELC morphology is unaffected by depletion of ULP1.

Magenta = anti-V5 detecting Vps9^{3xV5}, Green = anti-IMC6. F) Rhoptry morphology is

unaffected by depletion of ULP1. Magenta = anti-ROP7, Green = anti-IMC6. G)

Microneme morphology is unaffected by depletion of ULP1. Magenta = anti-MIC2, Green

= anti-IMC6. H) Dense granule morphology is unaffected by depletion of ULP1. Magenta

= anti-GRA12, Green = anti-IMC6. I) Apicoplast morphology is unaffected by depletion of

ULP1. Magenta = anti-ATrx1, Green = anti-IMC6. J) Mitochondrion morphology is

unaffected by depletion of ULP1. Magenta = anti-F1β ATPase, Green = anti-IMC6. Scale

bars = 2 μm.

Figure 3

A ULP1 | TurboID-3xHA
p115/Uso1-like domain | Coiled-Coil Domain

B

- Biotin

Phase | ULP1^TurboID | Strep | Merge

+ Biotin

Phase | ULP1^TurboID | Strep | Merge

C

	wt		ULP1^TurboID	
	-	+	-	+	Biotin

100
75
50
37
Strep

50
HA

37
ROP13

D ULP1^3xHA

WCL | IP

anti-HA

Fig 3. Validation of ULP1 TurboID and IP. A) The TurboID biotin ligase and a 3xHA tag

were fused to the C-terminus of ULP1 to generate the ULP1^{TurboID} line. B) IFA showing that

ULP1^{TurboID} localizes as expected and results in biotinylation of proximal proteins in a

biotin-dependent manner (yellow arrow). The apicoplast, which contains endogenously

biotinylated proteins, is denoted by white arrow. Magenta = anti-HA detecting ULP1^{TurboID},

Green = streptavidin. Scale bar = 2 µm. C) Western blot showing biotin-dependent

biotinylation of proteins in the ULP1^{TurboID} line, which is absent from a wild-type control.

ROP13 is used as a loading control. D) Western blot showing enrichment of ULP1^{3xHA}

after immunoprecipitation with anti-HA resin despite significant protein breakdown. WCL

= whole-cell lysate prior to IP. IP = final sample eluted from anti-HA resin.

Figure 4

Fig 4. ULP1 TurboID and IP hits reveals novel Golgi-associated proteins. IFAs and

corresponding gene models for 11 genes identified as candidate Golgi proteins in the

ULP1 TurboID and IP experiments. Each gene was endogenously tagged with mAID-

3xHA or mIAA7-3xHA auxin-inducible degrons. White arrows indicate that the protein

primarily colocalizes with GRASP55-YFP. Yellow arrows indicate that the protein primarily

localizes upstream of GRASP55-YFP. Cyan arrows indicate that the protein primarily

localizes downstream of GRASP55-YFP. A) TGGT1_311400 (Sec31) localizes upstream

of GRASP55 and contains a WD40 repeat domain. B) TGGT1_294730 (Sec16-L)

localizes upstream of GRASP55 and contains an ACE1 domain. C) TGGT1_264090

(TRAPPC11) colocalizes with GRASP55 and contains a TRAPPC11 domain. D)

TGGT1_290310 (COG1) colocalizes with GRASP55 and contains no identifiable

functional domains. E) TGGT1_232190 (GBF1) colocalizes with GRASP55 and contains

a GBF1 domain. F) TGGT1_207370 (GLP2) colocalizes with GRASP55 and contains

three predicted CC domains within residues 273-301, 313-373, and 382-423. G)

TGGT1_230400 (WPDP) colocalizes with GRASP55 and contains a large WASP-

interacting protein related domain. H) TGGT1_216370 (GLP3) localizes downstream of

GRASP55 and contains two predicted CC domains within residues 337-370 and 494-527.

I) TGGT1_ 301410 (Tepsin) localizes downstream of GRASP55 and contains ENTH and

Tepsin domains. J) TGGT1_258080 (GLP1) localizes downstream of GRASP55 and

contains five predicted CC domains within residues 1117-1332, 1362-1407, 1425-1464,

1603-1646, and 1659-1701. K) TGGT1_240220 (GLP4) localizes downstream of

GRASP55 and contains three predicted CC domains within residues 634-747, 797-830,

and 850-881. Magenta = anti-HA detecting degron-tagged proteins, Green = GRASP55-

YFP. Scale bars = 2 μm.

Figure 5

Fig 5. Conditional knockdown of Sec31, GBF1, COG1, Tepsin, and TRAPPC11. A)

Plaque assays were performed -/+ IAA to assess how depletion of Sec31, GBF1, COG1,

Tepsin, or TRAPPC11 affects overall lytic ability over the course of seven days. Number

of plaques was quantified for each condition. Statistical significance was determined using

multiple two-tailed t tests (**** = $P < 0.0001$, *** = $P < 0.001$) B, C) Depletion of Sec31 or

GBF1 results in growth arrest. Depletion of GBF1 additionally leads to morphological

defects in some parasites (white arrow). C, D) Depletion of COG1 or Tepsin results in

morphological defects (white arrows). F) Depletion of TRAPPC11 does not result in any

obvious defects in morphology. Magenta = anti-HA detecting degron-tagged proteins,

Green = anti-IMC6. Scale bars = 2 µm.

Figure 6

Fig 6. Conditional knockdown of Sec16-L, WPDP, GLP1, GLP2, GLP3, and GLP4.

A) Plaque assays were performed -/+IAA to assess how depletion of Sec16-L, WPDP,

GLP1, GLP2, GLP3, and GLP4 affects overall lytic ability over the course of seven days.

Mean plaque area was quantified for each condition. Statistical significance was

determined using multiple two-tailed t tests (**** = P < 0.0001, *** = P < 0.001, ** = P <

0.01, * = P <0.05.) B-G) Depletion of Sec16-L, WPDP, GLP1, GLP2, GLP3, or GLP4 does

not result in any obvious defects in morphology. Magenta = anti-HA detecting degron-

tagged proteins, Green = anti-IMC6. Scale bars = 2 μm.

Table 1

Gene ID	Abbrv.	Protein Name	TurboID		IP		ToxoDB Annotation	GWCS
			Ctrl	Exp	Ctrl	Exp		
TGGT1_289120	ULP1	Uso1-Like Protein 1	1.5	341	0	382	hypothetical protein	-3.8
TGGT1_311400	Sec31	Secretory 31	28	698.5	0	0	WD domain, G-beta repeat-containing protein	-5.53
TGGT1_294730	Sec16-L	Sec16-like Protein	12	468	0	0	hypothetical protein	-2.21
TGGT1_264090	TRAPPC11	Trafficking protein particle complex subunit 11	2	326.5	0	0	hypothetical protein	-4.74
TGGT1_290310	COG1	Conserved Oligomeric Golgi complex component 1	0	199	0	59	hypothetical protein	-3.75
TGGT1_232190	GBF1	Golgi Brefeldin A resistance guanine nucleotide exchange Factor 1	1	157	0	0	Sec7 domain-containing protein	-5.57
TGGT1_207370	GLP2	Golgi Localizing Protein 2	1	126.5	0	0	hypothetical protein	-3.89
TGGT1_230400	WPDP	WIP-related Protein Domain-containing Protein	2	67	0	0	hypothetical protein	-2.42
TGGT1_216370	GLP3	Golgi Localizing Protein 3	0	46	0	38	hypothetical protein	-4.37
TGGT1_301410	Tepsin	AP-4 complex accessory subunit Tepsin	0	41	0	0	hypothetical protein	-4.16
TGGT1_258080	GLP1	Golgi Localizing Protein 1	0	32.5	0	0	hypothetical protein	-2.41
TGGT1_240220	GLP4	Golgi Localizing Protein 4	0	20	0	0	hypothetical protein	-2.1

Table 1. Summary of Golgi-associated proteins identified in this study. Table

summarizing the twelve novel Golgi-associated proteins identified and characterized in

this study, listed in order of enrichment in the ULP1 TurboID experiment. Average spectral

counts for each protein in the TurboID and IP experiments are shown ("Ctrl" = control,

"Exp" = experimental). GWCS = phenotype score assigned in a genome wide

CRISPR/Cas9 screen (33). Abbrv. = protein name abbreviation.

Table S1. ULP1 TurboID results.

List of genes identified by mass spectrometry in the ULP1 TurboID experiment. Spectral

counts are shown for each gene. "Enrichment Diff" refers to the difference between the

average spectral count in ULP1^{TurboID} and control parasites. "Enrichment Fold" refers to

the average spectral count for ULP1^{TurboID} samples divided by the average spectral count

for control samples. GWCS = phenotype score assigned in a genome wide CRISPR/Cas9

screen (33). SP = signal peptide. #TMDs = number of transmembrane domains.

Table S2. ULP1 immunoprecipitation results.

List of genes identified by mass spectrometry in the ULP1 immunoprecipitation

experiment. Spectral counts are shown for each gene. "Enrichment Diff" refers to the

difference between the spectral count in ULP1^{3xHA} IP versus control experiments.

"Enrichment Fold" refers to the spectral count for the ULP1^{3xHA} IP sample divided by the

spectral count for the control sample. GWCS = phenotype score assigned in a genome

wide CRISPR/Cas9 screen (33). SP = signal peptide. #TMDs = number of transmembrane

domains.

Table S3. Oligonucleotides used in this study.

References

1. Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe
malaria. Trends Parasitol. 2004 Dec;20(12):597–603.

2. Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. The Burden
of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in
Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing
Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis. 2016
May;10(5):e0004729.

3. Sharman PA, Smith NC, Wallach MG, Katrib M. Chasing the golden egg: vaccination
against poultry coccidiosis. Parasite Immunol. 2010 Aug;32(8):590–8.

4. Kivaria FM. Estimated direct economic costs associated with tick-borne diseases on
cattle in Tanzania. Trop Anim Health Prod. 2006 May;38(4):291–9.

5. Dubey JP. Review of Neospora caninum and neosporosis in animals. Korean J
Parasitol. 2003 Mar;41(1):1–16.

6. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of
Toxoplasma gondii seroprevalence and implications for pregnancy and congenital
toxoplasmosis. Int J Parasitol. 2009 Oct;39(12):1385–94.

7. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans.
International Journal for Parasitology. 2000 Nov;30(12–13):1217–58.

8. Luft BJ, Remington JS. Toxoplasmic Encephalitis in AIDS. Clinical Infectious
Diseases. 1992 Aug 1;15(2):211–22.

9. Martin S. Congenital Toxoplasmosis. Neonatal Network. 2001 Jun;20(4):23–30.

10. Hager KM, Striepen B, Tilney LG, Roos DS. The nuclear envelope serves as an
intermediary between the ER and Golgi complex in the intracellular parasite
Toxoplasma gondii. J Cell Sci. 1999 Aug;112 (Pt 16):2631–8.

11. Tomavo S, Slomianny C, Meissner M, Carruthers VB. Protein trafficking through the
endosomal system prepares intracellular parasites for a home invasion. PLoS
Pathog. 2013 Oct;9(10):e1003629.

12. Joiner KA, Roos DS. Secretory traffic in the eukaryotic parasite Toxoplasma gondii:
less is more. J Cell Biol. 2002 May 13;157(4):557–63.

13. Gubbels MJ, Duraisingh MT. Evolution of apicomplexan secretory organelles. Int J
Parasitol. 2012 Nov;42(12):1071–81.

14. Nishi M, Hu K, Murray JM, Roos DS. Organellar dynamics during the cell cycle of
Toxoplasma gondii. Journal of Cell Science. 2008 May 1;121(9):1559–68.

15. McGovern OL, Rivera-Cuevas Y, Kannan G, Narwold AJ, Carruthers VB.
Intersection of endocytic and exocytic systems in Toxoplasma gondii. Traffic. 2018
May;19(5):336–53.

16. Stasic AJ, Moreno SNJ, Carruthers VB, Dou Z. The Toxoplasma plant-like vacuolar
compartment (PLVAC). J Eukaryot Microbiol. 2022 Nov;69(6):e12951.

17. Prasad A, Mastud P, Patankar S. Dually localised proteins found in both the
apicoplast and mitochondrion utilize the Golgi-dependent pathway for apicoplast
targeting in *Toxoplasma gondii*. Biol Cell. 2021 Jan;113(1):58–78.

18. Cao S, Yang J, Fu J, Chen H, Jia H. The Dissection of SNAREs Reveals Key
Factors for Vesicular Trafficking to the Endosome-like Compartment and Apicoplast
via the Secretory System in Toxoplasma gondii. mBio. 2021 Aug 31;12(4):e0138021.

19. Miranda K, Pace DA, Cintron R, Rodrigues JCF, Fang J, Smith A, et al.
Characterization of a novel organelle in Toxoplasma gondii with similar composition
and function to the plant vacuole. Mol Microbiol. 2010 Jun;76(6):1358–75.

20. Parussini F, Coppens I, Shah PP, Diamond SL, Carruthers VB. Cathepsin L
occupies a vacuolar compartment and is a protein maturase within the endo/exocytic
system of Toxoplasma gondii. Mol Microbiol. 2010 Jun;76(6):1340–57.

21. Morlon-Guyot J, Pastore S, Berry L, Lebrun M, Daher W. Toxoplasma gondii Vps11,
a subunit of HOPS and CORVET tethering complexes, is essential for the
biogenesis of secretory organelles. Cell Microbiol. 2015 Aug;17(8):1157–78.

22. Sloves PJ, Delhaye S, Mouveaux T, Werkmeister E, Slomianny C, Hovasse A, et al.
Toxoplasma sortilin-like receptor regulates protein transport and is essential for
apical secretory organelle biogenesis and host infection. Cell Host Microbe. 2012
May 17;11(5):515–27.

23. Breinich MS, Ferguson DJP, Foth BJ, van Dooren GG, Lebrun M, Quon DV, et al. A
dynamin is required for the biogenesis of secretory organelles in Toxoplasma gondii.
Curr Biol. 2009 Feb 24;19(4):277–86.

24. Klinger CM, Klute MJ, Dacks JB. Comparative genomic analysis of multi-subunit
tethering complexes demonstrates an ancient pan-eukaryotic complement and
sculpting in Apicomplexa. PLoS One. 2013;8(9):e76278.

25. Jimenez-Ruiz E, Morlon-Guyot J, Daher W, Meissner M. Vacuolar protein sorting
mechanisms in apicomplexan parasites. Mol Biochem Parasitol. 2016;209(1–2):18–
25.

26. Chen AL, Kim EW, Toh JY, Vashisht AA, Rashoff AQ, Van C, et al. Novel
components of the Toxoplasma inner membrane complex revealed by BioID. Mbio.
2015;6(1):e02357-14.

27. Sayers EW, Bolton EE, Brister JR, Canese K, Chan J, Comeau DC, et al. Database
resources of the national center for biotechnology information. Nucleic Acids Res.
2022 Jan 7;50(D1):D20–6.

28. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal
for protein modeling, prediction and analysis. Nat Protoc. 2015 Jun;10(6):845–58.

29. Heo Y, Yoon HJ, Ko H, Jang S, Lee HH. Crystal structures of Uso1 membrane tether
reveal an alternative conformation in the globular head domain. Sci Rep. 2020 Jun
12;10(1):9544.

30. Paysan-Lafosse T, Blum M, Chuguransky S, Grego T, Pinto BL, Salazar GA, et al.
InterPro in 2022. Nucleic Acids Res. 2023 Jan 6;51(D1):D418–27.

31. Ludwiczak J, Winski A, Szczepaniak K, Alva V, Dunin-Horkawicz S. DeepCoil-a fast
and accurate prediction of coiled-coil domains in protein sequences. Bioinformatics.
2019 Aug 15;35(16):2790–5.

32. Marsilia C, Batra M, Pokrovskaya ID, Wang C, Chaput D, Naumova DA, et al.
Essential role of the conserved oligomeric Golgi complex in Toxoplasma gondii.
mBio. 2023 Nov 15;14(6):e0251323.

33. Sidik SM, Huet D, Ganesan SM, Huynh MH, Wang T, Nasamu AS, et al. A Genome-
wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Cell.
2016;166(6):1423-1435.e12.

34. Sidik SM, Hackett CG, Tran F, Westwood NJ, Lourido S. Efficient Genome
Engineering of Toxoplasma gondii Using CRISPR/Cas9. Blader IJ, editor. PLoS
ONE. 2014 Jun 27;9(6):e100450.

35. Shen B, Brown KM, Lee TD, Sibley LD. Efficient Gene Disruption in Diverse Strains
of Toxoplasma gondii Using CRISPR/CAS9. Weiss LM, editor. mBio. 2014 May
13;5(3):e01114-14.

36. Pelletier L, Stern CA, Pypaert M, Sheff D, Ngô HM, Roper N, et al. Golgi biogenesis
in Toxoplasma gondii. Nature. 2002 Aug 1;418(6897):548–52.

37. Brown KM, Long S, Sibley LD. Conditional Knockdown of Proteins Using Auxin-
inducible Degron (AID) Fusions in Toxoplasma gondii. Bio Protoc. 2018 Feb
20;8(4):e2728.

38. Nishimura K, Fukagawa T, Takisawa H, Kakimoto T, Kanemaki M. An auxin-based
degron system for the rapid depletion of proteins in nonplant cells. Nat Methods.
2009 Dec;6(12):917–22.

39. Back PS, Moon AS, Pasquarelli RR, Bell HN, Torres JA, Chen AL, et al. IMC29
Plays an Important Role in Toxoplasma Endodyogeny and Reveals New
Components of the Daughter-Enriched IMC Proteome. mBio. 2023 Feb
28;14(1):e0304222.

40. Beck JR, Rodriguez-Fernandez IA, Cruz de Leon J, Huynh MH, Carruthers VB,
Morrissette NS, et al. A Novel Family of Toxoplasma IMC Proteins Displays a
Hierarchical Organization and Functions in Coordinating Parasite Division. Soldati-
Favre D, editor. PLoS Pathog. 2010 Sep 9;6(9):e1001094.

41. Lamarque MH, Roques M, Kong-Hap M, Tonkin ML, Rugarabamu G, Marq JB, et al.
Plasticity and redundancy among AMA-RON pairs ensure host cell entry of
Toxoplasma parasites. Nat Commun. 2014 Jun 17;5:4098.

42. Branon TC, Bosch JA, Sanchez AD, Udeshi ND, Svinkina T, Carr SA, et al. Efficient
proximity labeling in living cells and organisms with TurboID. Nat Biotechnol.
2018;36(9):880–7.

43. Venugopal K, Werkmeister E, Barois N, Saliou JM, Poncet A, Huot L, et al. Dual role
of the Toxoplasma gondii clathrin adaptor AP1 in the sorting of rhoptry and
microneme proteins and in parasite division. PLoS Pathog. 2017
Apr;13(4):e1006331.

44. Sakura T, Sindikubwabo F, Oesterlin LK, Bousquet H, Slomianny C, Hakimi MA, et
al. A Critical Role for Toxoplasma gondii Vacuolar Protein Sorting VPS9 in Secretory
Organelle Biogenesis and Host Infection. Sci Rep. 2016 Dec 14;6:38842.

45. Sohda M, Misumi Y, Yoshimura SI, Nakamura N, Fusano T, Ogata S, et al. The
interaction of two tethering factors, p115 and COG complex, is required for Golgi
integrity. Traffic. 2007 Mar;8(3):270–84.

46. Amos B, Aurrecoechea C, Barba M, Barreto A, Basenko EY, Bażant W, et al.
VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource
center. Nucleic Acids Res. 2022 Jan 7;50(D1):D898–911.

47. Budnik A, Stephens DJ. ER exit sites - localization and control of COPII vesicle
formation. FEBS Lett. 2009 Dec 3;583(23):3796–803.

48. Nakajima H, Hirata A, Ogawa Y, Yonehara T, Yoda K, Yamasaki M. A cytoskeleton-
related gene, uso1, is required for intracellular protein transport in Saccharomyces
cerevisiae. J Cell Biol. 1991 Apr;113(2):245–60.

49. Sapperstein SK, Walter DM, Grosvenor AR, Heuser JE, Waters MG. p115 is a
general vesicular transport factor related to the yeast endoplasmic reticulum to Golgi
transport factor Uso1p. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):522–6.

50. Shorter J, Warren G. A role for the vesicle tethering protein, p115, in the post-mitotic
stacking of reassembling Golgi cisternae in a cell-free system. J Cell Biol. 1999 Jul
12;146(1):57–70.

51. Puthenveedu MA, Linstedt AD. Gene replacement reveals that p115/SNARE
interactions are essential for Golgi biogenesis. Proc Natl Acad Sci U S A. 2004 Feb
3;101(5):1253–6.

52. Noda Y, Yamagishi T, Yoda K. Specific membrane recruitment of Uso1 protein, the
essential endoplasmic reticulum-to-Golgi tethering factor in yeast vesicular transport.
J Cell Biochem. 2007 Jun 1;101(3):686–94.

53. Bravo-Plaza I, Tagua VG, Arst HN, Alonso A, Pinar M, Monterroso B, et al. The
Uso1 globular head interacts with SNAREs to maintain viability even in the absence
of the coiled-coil domain. Elife. 2023 May 30;12:e85079.

54. Kim S, Hill A, Warman ML, Smits P. Golgi disruption and early embryonic lethality in
mice lacking USO1. PLoS One. 2012;7(11):e50530.

55. Radulescu AE, Mukherjee S, Shields D. The Golgi protein p115 associates with
gamma-tubulin and plays a role in Golgi structure and mitosis progression. J Biol
Chem. 2011 Jun 17;286(24):21915–26.

56. Ibar C, Glavic Á. Drosophila p115 is required for Cdk1 activation and G2/M cell cycle
transition. Mech Dev. 2017 Apr;144(Pt B):191–200.

57. Allan BB, Moyer BD, Balch WE. Rab1 recruitment of p115 into a cis-SNARE
complex: programming budding COPII vesicles for fusion. Science. 2000 Jul
21;289(5478):444–8.

58. García-Mata R, Sztul E. The membrane-tethering protein p115 interacts with GBF1,
an ARF guanine-nucleotide-exchange factor. EMBO Rep. 2003 Mar;4(3):320–5.

59. Nakamura N, Lowe M, Levine TP, Rabouille C, Warren G. The vesicle docking
protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated
manner. Cell. 1997 May 2;89(3):445–55.

60. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta.
2013 Dec;1833(12):3460–70.

61. Salama NR, Chuang JS, Schekman RW. Sec31 encodes an essential component of
the COPII coat required for transport vesicle budding from the endoplasmic
reticulum. Mol Biol Cell. 1997 Feb;8(2):205–17.

62. Hu H, Gourguechon S, Wang CC, Li Z. The G1 Cyclin-dependent Kinase CRK1 in
Trypanosoma brucei Regulates Anterograde Protein Transport by Phosphorylating
the COPII Subunit Sec31. J Biol Chem. 2016 Jul 22;291(30):15527–39.

63. Claude A, Zhao BP, Kuziemsky CE, Dahan S, Berger SJ, Yan JP, et al. GBF1: A
novel Golgi-associated BFA-resistant guanine nucleotide exchange factor that
displays specificity for ADP-ribosylation factor 5. J Cell Biol. 1999 Jul 12;146(1):71–
84.

64. Szul T, Grabski R, Lyons S, Morohashi Y, Shestopal S, Lowe M, et al. Dissecting the
role of the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and
protein trafficking. J Cell Sci. 2007 Nov 15;120(Pt 22):3929–40.

65. Blackburn JB, D'Souza Z, Lupashin VV. Maintaining order: COG complex controls
Golgi trafficking, processing, and sorting. FEBS Lett. 2019 Sep;593(17):2466–87.

66. Smith RD, Lupashin VV. Role of the conserved oligomeric Golgi (COG) complex in
protein glycosylation. Carbohydr Res. 2008 Aug 11;343(12):2024–31.

67. Fauquenoy S, Hovasse A, Sloves PJ, Morelle W, Dilezitoko Alayi T, Slomianny C, et
al. Unusual N-glycan structures required for trafficking Toxoplasma gondii GAP50 to
the inner membrane complex regulate host cell entry through parasite motility. Mol
Cell Proteomics. 2011 Sep;10(9):M111.008953.

68. Tomita T, Sugi T, Yakubu R, Tu V, Ma Y, Weiss LM. Making Home Sweet and
Sturdy: Toxoplasma gondii ppGalNAc-Ts Glycosylate in Hierarchical Order and
Confer Cyst Wall Rigidity. mBio. 2017 Jan 10;8(1):e02048-16.

69. Borner GHH, Antrobus R, Hirst J, Bhumbra GS, Kozik P, Jackson LP, et al.
Multivariate proteomic profiling identifies novel accessory proteins of coated
vesicles. J Cell Biol. 2012 Apr 2;197(1):141–60.

70. Wallace NS, Gadbery JE, Cohen CI, Kendall AK, Jackson LP. Tepsin binds LC3B to
promote ATG9A export and delivery at the cell periphery. bioRxiv. 2023 Jul
18;2023.07.18.549521.

71. Scrivens PJ, Noueihed B, Shahrzad N, Hul S, Brunet S, Sacher M. C4orf41 and
TTC-15 are mammalian TRAPP components with a role at an early stage in ER-to-
Golgi trafficking. Mol Biol Cell. 2011 Jun 15;22(12):2083–93.

72. Whittle JRR, Schwartz TU. Structure of the Sec13-Sec16 edge element, a template
for assembly of the COPII vesicle coat. J Cell Biol. 2010 Aug 9;190(3):347–61.

73. Bharucha N, Liu Y, Papanikou E, McMahon C, Esaki M, Jeffrey PD, et al. Sec16
influences transitional ER sites by regulating rather than organizing COPII. Mol Biol
Cell. 2013 Nov;24(21):3406–19.

74. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, et al. Uncovering the
essential genes of the human malaria parasite Plasmodium falciparum by saturation
mutagenesis. Science. 2018 May 4;360(6388):eaap7847.

75. Egea G, Serra-Peinado C, Gavilan MP, Rios RM. Cytoskeleton and Golgi-apparatus
interactions: a two-way road of function and structure. CHC. 2015 Jan;37.

76. Munro S. The golgin coiled-coil proteins of the Golgi apparatus. Cold Spring Harb
Perspect Biol. 2011 Jun 1;3(6):a005256.

77. Donald RG, Roos DS. Stable molecular transformation of Toxoplasma gondii: a
selectable dihydrofolate reductase-thymidylate synthase marker based on drug-
resistance mutations in malaria. Proc Natl Acad Sci U S A. 1993 Dec
15;90(24):11703–7.

78. Kim K, Soldati D, Boothroyd JC. Gene replacement in Toxoplasma gondii with
chloramphenicol acetyltransferase as selectable marker. Science. 1993 Nov
5;262(5135):911–4.

79. Donald RG, Carter D, Ullman B, Roos DS. Insertional tagging, cloning, and
expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine
phosphoribosyltransferase gene: Use as a selectable marker for stable
transformation. J Biol Chem. 1996 Jun 14;271(24):14010–9.

80. Choi CP, Moon AS, Back PS, Jami-Alahmadi Y, Vashisht AA, Wohlschlegel JA, et
al. A photoactivatable crosslinking system reveals protein interactions in the
Toxoplasma gondii inner membrane complex. PLOS Biology. 2019 Oct
4;17(10):e3000475.

81. Francia ME, Wicher S, Pace DA, Sullivan J, Moreno SNJ, Arrizabalaga G. A
Toxoplasma gondii protein with homology to intracellular type Na$^+$/H$^+$ exchangers is
important for osmoregulation and invasion. Exp Cell Res. 2011 Jun
10;317(10):1382–96.

82. Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein
secretion in the protozoan parasite Toxoplasma gondii. Eukaryot Cell. 2007
Nov;6(11):2147–56.

83. Rome ME, Beck JR, Turetzky JM, Webster P, Bradley PJ. Intervacuolar transport
and unique topology of GRA14, a novel dense granule protein in Toxoplasma gondii.
Infect Immun. 2008 Nov;76(11):4865–75.

84. Carruthers VB, Sherman GD, Sibley LD. The Toxoplasma adhesive protein MIC2 is
proteolytically processed at multiple sites by two parasite-derived proteases. J Biol
Chem. 2000 May 12;275(19):14346–53.

85. DeRocher AE, Coppens I, Karnataki A, Gilbert LA, Rome ME, Feagin JE, et al. A
thioredoxin family protein of the apicoplast periphery identifies abundant candidate
transport vesicles in Toxoplasma gondii. Eukaryot Cell. 2008 Sep;7(9):1518–29.

86. Frénal K, Marq JB, Jacot D, Polonais V, Soldati-Favre D. Plasticity between MyoC-
and MyoA-glideosomes: an example of functional compensation in Toxoplasma
gondii invasion. PLoS Pathog. 2014 Oct;10(10):e1004504.

87. Bradley PJ, Ward C, Cheng SJ, Alexander DL, Coller S, Coombs GH, et al.
Proteomic Analysis of Rhoptry Organelles Reveals Many Novel Constituents for
Host-Parasite Interactions in Toxoplasma gondii. Journal of Biological Chemistry.
2005 Oct;280(40):34245–58.

88. Huynh MH, Carruthers VB. Tagging of endogenous genes in a Toxoplasma gondii
strain lacking Ku80. Eukaryot Cell. 2009 Apr;8(4):530–9.

89. Bradley PJ, Rayatpisheh S, Wohlschlegel JA, Nadipuram SM. Using BioID for the
Identification of Interacting and Proximal Proteins in Subcellular Compartments in
Toxoplasma gondii. Methods Mol Biol. 2020;2071:323–46.

90. Xu T, Park SK, Venable JD, Wohlschlegel JA, Diedrich JK, Cociorva D, et al.
ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and
specificity. Journal of Proteomics. 2015 Nov 3;129:16–24.

91. Tabb DL, McDonald WH, Yates JR. DTASelect and Contrast: Tools for Assembling
and Comparing Protein Identifications from Shotgun Proteomics. J Proteome Res.
2002 Feb 1;1(1):21–6.

92. Cociorva D, L. Tabb D, Yates JR. Validation of Tandem Mass Spectrometry
Database Search Results Using DTASelect. Current Protocols in Bioinformatics.
2006;16(1):13.4.1-13.4.14.

93. Florens L, Carozza MJ, Swanson SK, Fournier M, Coleman MK, Workman JL, et al.
Analyzing chromatin remodeling complexes using shotgun proteomics and
normalized spectral abundance factors. Methods. 2006 Dec 1;40(4):303–11.

94. Mistry J, Chuguransky S, Williams L, Qureshi M, Salazar GA, Sonnhammer ELL, et
al. Pfam: The protein families database in 2021. Nucleic Acids Res. 2021 Jan
8;49(D1):D412–9.

95. Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER:
Making genome-scale phylogenetics accessible to all. Protein Sci. 2022
Jan;31(1):8–22.